A5102922776- Diabetes Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Metabolism, Diabetes, and Cancer
- Heart Failure Treatment and Management
- Diabetes Management and Research
- Lipoproteins and Cardiovascular Health
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Function and Risk Factors
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Peripheral Artery Disease Management
- Pharmacology and Obesity Treatment
- Chronic Kidney Disease and Diabetes
- Venous Thromboembolism Diagnosis and Management
- Peptidase Inhibition and Analysis
- Cardiovascular Disease and Adiposity
- Hepatitis C virus research
- GDF15 and Related Biomarkers
- Statistical Methods in Clinical Trials
- Cardiac Imaging and Diagnostics
- Sex and Gender in Healthcare
- Potassium and Related Disorders
- Fibroblast Growth Factor Research
- Cardiac electrophysiology and arrhythmias
Thrombolysis in Myocardial Infarction Study Group
2016-2025
Brigham and Women's Hospital
2016-2025
Harvard University
2014-2025
Tokai University
2015
Women's College Hospital
2014-2015
University of Toronto
2014-2015
Toronto General Hospital
2014-2015
Sorbonne Paris Cité
2015
Assistance Publique – Hôpitaux de Paris
2015
Inserm
2015
The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety ticagrelor, P2Y12 receptor antagonist with established an acute coronary syndrome, in this context.We randomly assigned, double-blind 1:1:1 fashion, 21,162 patients who had to 3 years earlier ticagrelor at dose 90 mg twice daily, 60 or placebo. All were receive low-dose aspirin followed for median 33 months. primary end point was...
Diabetes mellitus and heart failure frequently coexist. However, few diabetes trials have prospectively evaluated adjudicated as an end point.A total of 16 492 patients with type 2 a history of, or at risk cardiovascular events were randomized to saxagliptin placebo (mean follow-up, 2.1 years). The primary point was the composite death, myocardial infarction, ischemic stroke. Hospitalization for predefined component secondary point. Baseline N-terminal pro B-type natriuretic peptide measured...
Background— Despite the known association of diabetes mellitus with cardiovascular events, there are few contemporary data on long-term outcomes from international cohorts patients mellitus. We sought to describe at 4 years and identify predictors these events in Methods Results— The Reduction Atherothrombosis for Continued Health (REACH) registry is an high risk atherothrombosis or established atherothrombosis. Four-year event rates were determined corrected group prognosis method. Of 45...
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.To evaluate efficacy and safety darapladib patients after acute coronary syndrome (ACS) event.SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 13,026 participants within 30 days hospitalization with ACS (non-ST-elevation or ST-elevation myocardial...
Dipeptidyl peptidase 4 inhibitors may have a protective effect in diabetic nephropathy.We studied renal outcomes of 16,492 patients with type 2 diabetes, randomized to saxagliptin versus placebo and followed for median 2.1 years the Saxagliptin Assessment Vascular Outcomes Recorded Patients Diabetes Mellitus-Thrombolysis Myocardial Infarction 53 (SAVOR-TIMI 53) trial.At baseline, 9,696 (58.8%) subjects had normoalbuminuria (albumin/creatinine ratio [ACR] <30 mg/g), 4,426 (26.8%)...
OBJECTIVE The glycemic management of patients with type 2 diabetes mellitus (T2DM) and renal impairment is challenging, few treatment options. We investigated the effect saxagliptin in Saxagliptin Assessment Vascular Outcomes Recorded Patients Diabetes Mellitus (SAVOR)-Thrombolysis Myocardial Infarction (TIMI) 53 trial according to baseline function. RESEARCH DESIGN AND METHODS T2DM at risk for cardiovascular events were stratified as having normal or mildly impaired function (estimated...
AimsTicagrelor reduced major adverse cardiovascular event (MACE) by 15–16% in patients with prior myocardial infarction (MI) PEGASUS-TIMI 54. We hypothesized that who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and derive benefit from continuation or reinitiation therapy.
<h3>Importance</h3> In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared placebo. However, more prematurely discontinued than <h3>Objective</h3> To investigate reasons and timing discontinuation prior infarction. <h3>Design, Setting, Participants</h3> 21 162 outpatients infarction were randomly assigned 90 mg twice daily, 60 placebo, all receiving a low dose aspirin....
An elevated level of urinary albumin to creatinine ratio (UACR) is a marker renal dysfunction and predictor kidney failure/death in patients with type 2 diabetes. The prognostic use UACR established cardiac biomarkers not well described.
Cardiac biomarkers provide insights into pathophysiologic processes and offer an attractive strategy for the assessment of cardiovascular risk.To assess incremental prognostic value that reflect different in patients with type 2 diabetes.The Saxagliptin Assessment Vascular Outcomes Recorded Patients Diabetes Mellitus (SAVOR)-Thrombolysis Myocardial Infarction (TIMI) 53 is a randomized, double-blind, placebo-controlled clinical trial evaluated safety saxagliptin vs placebo 16 492 outpatients...
Metformin is first-line therapy for type 2 diabetes mellitus, although its effects on the cardiovascular system are unproved.In this post hoc analysis, patients in SAVOR-TIMI 53 (Saxagliptin and Cardiovascular Outcomes Patients With Type Diabetes Mellitus) with baseline biomarker samples (n=12 156) were classified as ever versus never taking metformin during trial period. Associations between exposure outcomes estimated inverse probability of treatment weighting Cox modeling composite end...
We evaluated the relationship of renal function and ischaemic bleeding risk as well efficacy safety ticagrelor in stable patients with prior myocardial infarction (MI). Patients a history MI 1–3 years from PEGASUS-TIMI 54 were stratified based on estimated glomerular filtration rate (eGFR), <60 mL/min/1.73 m2 pre-specified for analysis effect primary composite cardiovascular death, MI, or stroke (major adverse events, MACE) endpoint TIMI major bleeding. Of 20 898 patients, those eGFR (N =...
To determine the incidence of pancreatitis and pancreatic cancer in SAVOR-TIMI 53 trial.A total 16,492 type 2 diabetic patients ≥40 years old with established cardiovascular (CV) disease or CV risk factors were randomized to saxagliptin placebo followed for 2.1 years. Outcome measures investigator reported blinded expert adjudication (acute chronic) cases cancer.Trial investigators 35 events each treatment arm 63 (33 [0.40%] 30 [0.37%] control arm), a hazard ratio (HR) 1.09 (95% CI...
Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths hospitalizations for heart failure (HHF) among patients with type diabetes. The relative CV efficacy safety of dapagliflozin according to baseline kidney function albuminuria status are unknown.
In acute coronary syndrome (ACS), potassium levels <3.5 mEq/L are associated with ventricular arrhythmias. Current guidelines therefore recommend a target >4.0 in ACS. Our study evaluated the association between levels, cardiac arrhythmias, and cardiovascular death patients non-ST-segment elevation myocardial infarction or unstable angina. Potassium were measured 6515 prior to randomization receive either ranolazine placebo MERLIN-TIMI 36 trial. A seven-day continuous electrocardiographic...